Atrial arrhythmogenesis in wild-type and Scn5a+/Δ murine hearts modelling LQT3 syndrome by Dautova, Yana et al.
CARDIOVASCULAR PHYSIOLOGY
Atrial arrhythmogenesis in wild-type and Scn5a+/Δ murine
hearts modelling LQT3 syndrome
Yana Dautova & Yanmin Zhang & Ian Sabir &
Andrew A. Grace & Christopher L.-H. Huang
Received: 7 November 2008 /Accepted: 25 December 2008 /Published online: 28 January 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Long QT(3) (LQT3) syndrome is associated with
abnormal repolarisation kinetics, prolonged action potential
durations (APD) and QT intervals and may lead to life-
threatening ventricular arrhythmias. However, there have
been few physiological studies of its effects on atrial
electrophysiology. Programmed electrical stimulation and
burst pacing induced atrial arrhythmic episodes in 16 out of
16 (16/16) wild-type (WT) and 7/16 genetically modified
Scn5a+/Δ (KPQ) Langendorff-perfused murine hearts
modelling LQT3 (P<0.001 for both), and in 14/16 WT
and 1/16 KPQ hearts (P<0.001 for both; Fisher’s exact
test), respectively. The arrhythmogenic WT hearts had
significantly larger positive critical intervals (CI), given by
the difference between atrial effective refractory periods
(AERPs) and action potential durations at 90% recovery
(APD90), compared to KPQ hearts (8.1 and 3.2 ms,
respectively, P<0.001). Flecainide prevented atrial arrhyth-
mias in all arrhythmogenic WT (P<0.001) and KPQ hearts
(P<0.05). It prolonged the AERP to a larger extent than it
did the APD90 in both WT and KPQ groups, giving
negative CIs. Quinidine similarly exerted anti-arrhythmic
effects, prolonged AERP over corresponding APD90 in
both WT and KPQ groups. These findings, thus, demon-
strate, for the first time, inhibitory effects of the KPQ
mutation on atrial arrhythmogenesis and its modification by
flecainide and quinidine. They attribute these findings to
differences in the CI between WT and mutant hearts, in the
presence or absence of these drugs. Thus, prolongation of
APD90 over AERP gave positive CI values and increased
atrial arrhythmogenicity whereas lengthening of AERP
over APD90 reduced such CI values and produced the
opposite effect.
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Introduction
Atrial tachycardia (AT) is characterised by an abnormal
rapid cardiac rhythm which can develop into atrial
fibrillation (AF). Its clinical incidence is influenced by
familial history and, therefore, genetic factors [9]. Re-
entrant substrates have been implicated in such phenomena
[2, 21]. In common with recent murine ventricular models
for long QT syndromes (LQTS) [27, 34, 40], previous
studies have attributed atrial arrhythmogenesis to decreased
tissue refractoriness or alterations in action potential
duration (APD) [1, 6, 24, 33, 48]. However, APD is
determined by the balance between a number of inward and
outward currents that flow during action potential restitu-
tion that could be specific for atrial tissue. Yet few studies
have examined for the existence of or characterised atrial as
opposed to ventricular arrhythmic phenotypes in LQTS
models. Atrial arrhythmias were reported as uncommon in
patients with the inherited LQTS who are susceptible to
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reported that LQTS patients demonstrated abnormalities in
atrial physiology similar to those found in the ventricle in
the form of prolonged APD and refractory period (RP)
durations and early after-depolarisations (EADs) triggering
‘atrial torsade de pointes’. This suggested that electrophys-
iological abnormalities seen in LQTS individuals could
predispose not only to ventricular but also to atrial
arrhythmias. However, this study included very few
LQT1, LQT2, long QT(3) (LQT3) and unidentified carriers.
LQT3 is one of the known LQTS variants; the causes of
LQT3 include ‘gain-of-function’ mutations in the inactiva-
tion domain between DIII and DIV of the Scn5a gene
encoding the α-(pore-forming) subunit of the cardiac
voltage-gated Na
+ channel responsible for initiating the
cardiac AP [38, 46, 47]. One such, ΔKPQ, mutation is a
deletion of nine bases that code for Lys-1505, Pro-1506,
Gln-1507, resulting in a prolonged APD. Scn5a+/Δ (KPQ)
mutant mice modelling human LQT3 have been success-
fully used to demonstrate AP and QT prolongation along
with torsade de pointes-like ventricular tachycardia, often
observed in humans with LQT3 [25, 28, 40]. Furthermore,
the cardiotropic Class I drugs, flecainide and quinidine
respectively exerted anti- and pro-arrhythmic effects on
KPQ hearts, but had precisely opposite effects in wild-type
(WT) hearts [39, 40]. These actions correlated directly with
the corresponding changes in endocardial and epicardial
APDs as well as the corresponding RPs.
However, in contrast to the ventricles, atria are thin-
walled structures less likely to generate these marked
transmural heterogeneities that have been associated with
ventricular arrhythmogenesis [3, 4, 40]. Yet, there are very
few studies that have investigated atrial arrhythmogenesis
in murine hearts [19, 42, 45]. Finally, to date, there has not
been a study investigating atrial arrhythmogenicity specif-
ically in KPQ mice modelling human LQT3. This investi-
gation, therefore, tests the hypothesis that factors previously
known to determine arrhythmias in ventricles do not
necessarily determine atrial arrhythmogenicity. It demon-
strated for the first time contrasting atrial electrophysiolog-
ical properties of WT and KPQ Langendorff-perfused
mouse hearts modelling LQT3 syndrome and that drugs
causing ventricular arrhythmogenecity do not have identical
effects in atrial tissue in WT and KPQ mouse hearts.
Methods
Experimental animals
WT and heterozygote Scn5a+/Δ (KPQ) mice breeding pairs
both with a 129 genetic background were set up and their
offspring genotyped, weaned and used for this study. Mice
aged 5 to 9 months were used in all experiments. All mice
were maintained in an animal house at room temperature,
subjected to 12 h light–dark cycle, and had a free access to
sterile rodent chow and water at all times. All procedures
were in accordance with the UK Animals (Scientific
Procedures) Act 1986.
Experimental preparations
Langendorff-perfused whole heart preparations were used
for electrophysiological studies, as previously described by
Balasubramaniam et al. [5] and Head et al. [12]. Animals
were randomly selected and killed in accordance with
Schedule 1: Animals (Scientific Procedures) Act 1986 by
cervical dislocation. Whole hearts were then quickly
excised and submerged in ice-cold bicarbonate-buffered
Krebs–Henseleit solution prepared from (mM): 119 NaCl,
25 NaHCO3, 4.0 KCl, 1.2 KH2PO4, 1.0 MgCl2, 1.8 CaCl2,
10 glucose and 2.0 sodium pyruvate (pH 7.4). The solution
was then bubbled with 95% O2–5% CO2 (British Oxygen
Company, Manchester, UK). The aorta was cannulated and
then sutured to a 21-gauge custom-made cannula prefilled
with ice-cold buffer while the heart was fully submerged in
Krebs–Henseleit solution. The preparation was then
mounted onto a perfusion apparatus which allowed a
warmed (37°C) Krebs–Henseleit buffer solution to pass
through the heart via the aorta at a constant flow rate of
2.5–3.0 ml min
−1 (Watson–Marlow Bredel Peristaltic
pumps, model 505S, Falmouth, Cornwall, UK). Before
entering the heart, the perfusate was passed through 200-
and 5-μm filters (Millipore UK, Watford, UK). Hearts that
regained a pink colouration and spontaneous rhythmic
contractions upon warming were used in the experiments.
Electrophysiological procedures
On warming and regaining a healthy pink colour and a
normal heart beat, hearts were allowed to spontaneously
beat for at least 10 min before proceeding with programmed
electrical stimulation (PES) [30, 31] and burst pacing (BP)
as described below. Paired (1 mm inter-pole spacing)
platinum stimulating and recording electrodes were posi-
tioned against the epicardial surfaces of the right and the
left atrium, respectively, which allowed bipolar electro-
grams (BEGs) to be recorded from atria and ventricles.
BEGs were amplified, band-pass filtered (30 Hz–1 kHz;
Gould 2400S, Gould-Nicolet Technologies, Ilford, Essex,
UK) and digitised (1401plus, Cambridge Electronic Design,
Cambridge, UK) at a frequency of 5 kHz. In addition, a
third electrode was placed on the basal epicardial surface of
the left ventricle in order to obtain a simultaneous BEG
signal from the left ventricle only. The procedure of
simultaneous atrial and ventricular recording made it
444 Pflugers Arch - Eur J Physiol (2009) 458:443–457possible to separate contributions to electrical activity from
each structure in the observed BEG recordings.
A paired platinum pacing electrode connected to Grass
S48 stimulator (Grass-Telefactor, UK, Slough, UK) was
used to pace the heart at the right atrium at 3.5 V. On
positioning of all electrodes, each heart was briefly paced at
a frequency of 8 Hz using 2 ms square-wave stimuli to
ensure consistent capture and good quality signals. Upon
acquiring a clear signal, the position of the stimulation and
recording electrodes was fixed.
To assess tendencies to atrial arrhythmogenesis, two
procedures were used. Firstly, each heart was subjected to
PES. This consisted of drive trains of eight paced S1 beats
at 8 or 10 Hz that were then followed by S2 extrastimuli
every ninth beat. The S1–S2 interval was initially equal to
the pacing interval and then reduced by 1 ms between
successive drive trains until the preparation became
refractory and no electrogram could be elicited by the S2
stimulus, or arrhythmic episode was initiated. If arrhythmia
supervened, pacing was terminated in order to confirm its
persistence or otherwise. Each heart was first subjected to
PES stimulation conducted at 8 Hz; this was repeated three
times and followed by PES stimulation conducted at 10 Hz
that was also repeated three times.
Secondly, each heart was exposed to a modified BP
protocol that was previously used to induce atrial arrhyth-
mias in mice [19]. The alternative protocol involved
delivering 25 trains of 50 stimuli imposed at high frequency
(20 ms between each stimulus) to the right atrium of a
spontaneously beating heart. Each successive train was
delivered as soon as the heart had recovered from the
preceding stimulation by returning to normal sinus rhythm.
In addition to BEGs, atrial monophasic action potentials
(MAPs) were recorded from atrioventricular (AV)-node-
ablated hearts. The left atrial appendage was pressed
against the clip using an epicardial MAP electrode (Linton
Instruments, Harvard Apparatus). This resulted in a
recording of atrial MAP signals. The heart was then paced
at 8 and 10 Hz stimulation frequencies using a pacing
electrode described above. MAPs were amplified, band-
pass filtered (0.5 Hz–1 kHz, Gould 2400S, Gould-Nicolet
Technologies, Ilford, Essex, UK) and digitised (1401plus,
Cambridge Electronic Design, Cambridge, UK) at a
frequency of 5 kHz.
The abovementioned electrophysiological procedures
were recorded in the presence and absence of pharmaco-
logical intervention. Only arrhythmias of more than six
cycles in duration were included in the analysis. Atrial
MAPs included in analysis satisfied previously described
criteria including a rapid upstroke phase with consistent
amplitude, a smooth contoured repolarisation phase and a
stable baseline [8]. APDs were determined at 90%
repolarisation level, where full repolarisation to baseline
level was defined as 100% and the tip of each MAP
upstroke as 0% repolarisation.
Data analysis and statistics
BEGs were captured and analysed using Spike5 software
(Cambridge Electronic Design, Cambridge, UK). All data
were imported into Microsoft EXCEL which was also used
to construct graphs and figures. All data are expressed as
means ± SEM. The sets of data were compared using
ANOVA (SPSS software) and P values less than 0.05 were
considered significant.
Reagents
Flecainide and quinidine (Sigma–Aldrich, Poole, UK) were
dissolved in doubly distilled water to make 1.0-mM stock
solutions. Final drug concentrations to be used in the
experiments (1 and 3 μM for both flecainide and quinidine)
were determined by testing five different concentrations
(100 nM, 1, 3, 5 and 10 μM) of the drugs. Final drug
concentrations were prepared by dilution of 1.0-mM stock
solutions in buffer to 10 μM first and then further dilutions
to the required concentrations. Flecainide was stored in the
refrigerator at 4°C between experiments and quinidine at
room temperature with aluminium foil wrapped around a
tightly sealed container to prevent light degradation. Hearts
were perfused with drugs for 15–20 min prior to PES and
BP.
Results
KPQ hearts show lower incidences and shorter durations
of atrial arrhythmias under both testing procedures
Two techniques were used to assess atrial arrhythmogenic
tendency in each WT (n=16; Figs. 1 and 2) and genetically
modified Scn5a+/Δ (KPQ) murine heart (n=16) using BEG
recordings. First, three cycles of a PES procedure con-
ducted at a pacing frequency of 8 Hz imposed trains of
eight pacing (S1) stimuli each followed by a ninth S2 extra
stimulus at progressively decreasing S1S2 intervals (exem-
plified by Fig. 1A) until either atrial refractoriness was
reached (Fig. 1B) or atrial arrhythmogenesis took place
(Fig. 1C). The procedure was then similarly repeated three
times at a pacing frequency of 10 Hz. This procedure
permitted both assessment of atrial arrhythmogenic tenden-
cy and determination of atrial RPs. Secondly, an atrial BP
procedure delivered 25 trains of 50 S1 stimuli at a high
frequency (corresponding to a S1S1 coupling interval of
20 ms) to the right atrium of a spontaneously beating heart
(Fig. 2A). This was followed by an assessment for either an
Pflugers Arch - Eur J Physiol (2009) 458:443–457 445immediate return to sinus rhythm (Fig. 2B) or the onset of
atrial arrhythmias (Fig. 2C). Each successive train was
delivered once the heart had regained its normal sinus
rhythm. The present protocols, thus, differed from our
previous studies on ventricular arrhythmogenesis [12, 27,
39, 40] in requiring hearts to be paced from the atria rather
than the ventricles. In some hearts, such higher pacing rates
resulted in a gradual development of an AV block
particularly at the higher (10 Hz) pacing rate. Nevertheless,
withdrawal of the regular pacing allowed a resumption of
intrinsic activity and permitted restoration of normal 1:1 AV
conduction. Such AV block was also observed during both
the PES and the BP procedures. These findings could relate
to longer refractoriness in the AV node.
Table 1 demonstrates lower levels of atrial arrhythmo-
genic tendency in KPQ (n=16) compared to WT hearts (n=
16) with all three test procedures. Firstly, all 16 WT hearts
showed at least one arrhythmic episode during PES
conducted at stimulation frequencies of either 8 or 10 Hz.
In contrast, only seven KPQ hearts displayed such arrhyth-
mogenic tendency with the same procedures. Fisher’s exact
Fig. 1 Assessment of atrial arrhythmogenesis using a programmed
electrical stimulation procedure. Simultaneously recorded atrial (A, B
and C, a) and ventricular (A, B and C, b) BEG traces obtained from a
typical WT heart in response to pacing conducted at a 10 Hz
stimulation frequency. The single vertical markers indicate the timing
of S1 stimuli (stim S1), the double vertical markers represent S2 extra-
stimuli (stim S2). A (a), Typical data obtained at the beginning of the
PES procedure at a longer S1S2 interval. A succession of three S1
stimulation artefacts and their respective evoked atrial (“A”) and
ventricular (“V”) electrograms are succeeded by the extrastimulus (S2)
artefact and its resulting atrial electrogram (“A2”) which is then
followed by the first of eight S1 stimulation artefacts and its
corresponding “A” and “V” electrograms. A, b shows simultaneously
recorded signals from the left ventricle and excludes the atrial
contributions. B (a) Typical data obtained when atrial refractoriness
is observed. The third S1 stimulation artefact is closely followed by a
S1 evoked “A” electrogram and S2 stimulation artefact. It is clearly
seen that the S2 premature stimulus failed to produce a corresponding
“A2” atrial signal which indicates atrial refractoriness. The signal
following the S2 stimulation artefact is a “V” electrogram which is
confirmed by the corresponding “V” electrogram in the bottom trace
(B, b). C (a), Typical data showing initiation of atrial arrhythmogenic
episode (AA) in response to a premature S2 stimulus. The S1
stimulation artefact is closely followed by a S1 evoked “A”
electrogram and S2 stimulation artefact which is in turn succeeded
by a “V” electrogram and AT. The bottom trace (C, b) confirms the
atrial origin of the tachycardia as no ventricular activity is observed at
the time when atrium is tachycardic at the top trace (C, a)
Fig. 2 Assessment of atrial arrhythmogenesis using atrial burst
pacing. Typical baseline sinus rhythm recording from a WT heart,
where each regularly occurring atrial (“A”) signal is followed by a
corresponding ventricular (“V”) signal (A). A train of 50 high
frequency S1 stimuli results in either an immediate return to a normal
sinus rhythm (B) or initiation of an atrial arrhythmic episode (AA) with
irregular ventricular activity (C)
446 Pflugers Arch - Eur J Physiol (2009) 458:443–457test accordingly confirmed highly significant differences for
atrial arrhythmogenicity between the two groups for both
PES procedures (P<0.001 in both cases). BP was less
effective in inducing arrhythmogenesis in either group.
Nevertheless, it also yielded clear-cut differences between
numbers of WT (14 out of 16) and KPQ hearts (one out of
16) showing atrial arrhythmias, similarly giving highly
significant differences between the two experimental groups
(P<0.001). Secondly, where arrhythmic episodes did occur,
they showed longer durations in the WT than in the KPQ
hearts through all three procedures, but with a larger spread
in values particularly in the WT group, which is reflected in
the SEM. Therefore, it was necessary to perform further
breakdowns of the arrhythmic frequencies. These analyses
that followed provided closer measures of the mean
incidence of atrial arrhythmias lasting six or more cycles
for each heart and their severity.
A third measure describing the mean overall incidence of
atrial arrhthymogenesis was, therefore, obtained for each
heart in the WT and mutant groups subject to each of the
test procedures (Fig. 3). The incidence of atrial arrrhythmo-
genesis following each pulse train during the three cycles of
PES at 8 and 10 Hz, respectively (Fig. 3A and B), as well
as during the 25 burst pacing procedures were obtained for
each heart (Fig. 3C). This permitted mean values to be
obtained for each experimental group.
Figure 3A demonstrates the WT murine hearts (n=16)
showed significantly higher mean overall incidences of
arrhythmic episodes per heart than KPQ (n=16) hearts
during PES whether at 8 Hz (P=0.01; Fig. 3A, a) or 10 Hz
(P<0.0001; Fig. 3B, a) stimulation frequencies and during
BP (P=0.0007; Fig. 3C, a). Furthermore, arrhythmic
episodes were significantly more frequent in WT hearts
paced at the higher frequency during PES (P=0.007); this
was not the case for KPQ hearts (P>0.05).
Finally, such arrhythmic episodes were sorted by duration
(atrial arrhythmia lasting≤1s ;1 . 1 –5.0 s; 5.1–10 s; and 10.1 s
and longer). This provided mean incidences of atrial
arrhythmias within each category within the two, WT (n=
16) and KPQ (n=16) experimental groups.
Figure 3 also shows that for both, PES and BP,
procedures, and both experimental groups, a significant
proportion of atrial arrhythmias observed fell into a
category with the lowest range of arrhythmic durations
(episodes lasting≤1 s; Fig. 3A–C, panel b). However, the
mean incidences of arrhythmic episodes per heart for this
category was significantly lower in the KPQ than the WT
group whether PES was conducted at stimulation frequen-
cies of 8 Hz (P=0.03) and 10 Hz (P<0.0001) and BP (P=
0.02). The mean incidence of arrhythmic episodes per heart
for arrhythmias lasting between 1.1–5.0 and 5.1–10.0 s was
also significantly lower in KPQ hearts for the BP procedure
(P=0.03 for both), and for arrhythmias lasting 10.1 s and
longer for PES conducted at 8 Hz (P=0.05). Finally, no
KPQ hearts displayed arrhythmias lasting more than 5.1 s
whereas we observed a total number of 24 separate
episodes of atrial arrhythmias of this duration; these
occurred in six WT hearts during both experimental
procedures.
Flecainide and quinidine both inhibit atrial
arrhythmogenesis
The experiments then went on to compare the effects of
quinidine and flecainide on atrial arrhythmogenesis. This
yielded patterns of action that contrasted with previous
reports of these agents on ventricular arrhythmogenesis in
the same murine system [39, 40].
Table 2 summarises the number of hearts in each group
that showed one or more arrhythmic episodes during any
one of the adopted test procedures. It shows that in WT
hearts, 1 μM flecainide exerted a significant reduction in
arrhythmogenic incidence during PES conducted at a
frequency of 10 Hz and during BP (P<0.01 in both cases;
Table 1 Atrial arrythmogenicity in WT and KPQ hearts
Genotype WT KPQ
No of hearts showing
AAs
Mean overall duration of
AA/heart (ms)
No of hearts showing
AAs
Mean overall duration of
AA/heart (ms)
PES (8 Hz) 16/16 1986±839 (n=16) 7/16 602±189 (n=7)
PES (10 Hz) 16/16 1524±505 (n=16) 7/16 859±354 (n=7)
BP 14/16 3560±1411 (n=16) 1/16 240 (n=1)
Number of WT (n=16) and KPQ (n=16) hearts that showed one or more episodes of atrial arrhythmias during PES and BP testing procedures and
the mean overall durations (± SEM) of such AA episodes. Both the number (m1) of hearts that displayed AA and the total number of hearts used
for the specific test procedure (m2) are shown (in the form m1/m2). For example, “7/16” indicates that seven hearts were arrhythmic out of 16
hearts tested)
WT wild-type, KPQ Scn5a+/Δ, PES programmed electrical stimulation, BP burst pacing
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effects through all the tests that were imposed (P<0.001 for
all three procedures). In KPQ hearts, 1 μM flecainide
completely abolished arrhythmogenic phenomena through
all the tests employed, with statistically significant effects
obtained with PES conducted at an 8-Hz stimulation
frequency (P<0.05); 3 μM flecainide resulted in a loss of
capture in the KPQ preparations which precluded detailed
study.
Tables 3 and 4 summarise the effects of flecainide and
quinidine, respectively, on mean overall incidences of atrial
arrhythmic episodes per heart through the WT or KPQ
hearts that were studied. In the WT preparations, flecainide
(1 μM) reduced the average total incidences of arrhythmic
episodes per heart whether these were undergoing PES at
stimulation frequencies of both 8 Hz (P=0.07) and 10 Hz
(P=0.002), and BP (P=0.05) and higher (3 μM) concen-
trations completely abolished all such arrhythmic phenom-
ena (P=0.03, P<0.0001 and P=0.01, respectively). KPQ
preparations required lower (1 μM) flecainide concentra-
tions to achieve such a complete abolition of arrhythmias
(P=0.02, P=0.06) with PES at 8 and 10 Hz; the BP protocol
resulted in low mean total incidences of atrial arrhythmic
episodes per heart in both control and treated groups, and
this accounts for the lack of significance between the two
results (P=0.34).
Table 3 also provides a summary of the effects of
flecainide on the breakdown of arrhythmic episodes sorted
Fig. 3 Overall and average incidence of atrial arrhythmic episodes
(AAs) per heart in WT and KPQ preparations. Overall (a in A–C) and
average (b in A–C) incidence of AAs per heart in WT (empty bars)
and KPQ hearts (filled bars) for PES conducted at 8 Hz (A, a and b)
and 10 Hz (B, a and b) stimulation frequencies and BP (C, a and b).
The results of one-way ANOVA for correlated samples are shown
(*P<0.05, **P<0.005 and ***P<0.0005) and compare average and
overall incidence of AA per heart between WT (n=16) and KPQ
(n=16) groups
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hearts, flecainide whether applied at 1 or 3 μM, signifi-
cantly reduced mean incidences of arrhythmic episodes
lasting≤1.0 s, during PES whether conducted at stimulation
frequencies of 8 Hz (P=0.03 and P=0.02, respectively) or
10 Hz (P=0.002 and P=0.0003, respectively). In the KPQ
group, flecainide similarly reduced the incidence of such
episodes lasting ≤1.0 s: 1 μM rather than 3 μM flecainide
sufficed to abolish all atrial arrhytmias whether PES was
conducted at 8 Hz (P= 0 . 0 4 )a n d1 0H z( P=0.02)
stimulation frequencies.
BP resulted in relatively low incidences of arrhythmic
episodes per heart in both WT and KPQ whether in the
presence or the absence of flecainide; the only one out of
six hearts that displayed a short (0.24 s) atrial arrhythmic
episode failed to show any with 1 μM flecainide.
In common with flecainide, quinidine was anti-arrhythmic
in both KPQ and WT hearts. Table 5 confirms that in the
Table 2 Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of flecainide (1 and 3 μM)
Genotype WT KPQ
Condition Control Flecainide 1 μM Flecainide 3 μM Control Flecainide 1 μM Flecainide 3 μM
PES (8 Hz) 11/11 4/6 0/5 5/6 0/6 X
PES (10 Hz) 11/11 2/6 0/5 4/6 0/6 X
BP 11/11 2/6 0/5 1/6 0/6 X
Numbers of hearts in which one or more episodes of atrial arrhythmias occurred out of the total number of preparations studied under that
condition (for example, 11/11 denotes that 11 hearts were arrhythmic out of 11 hearts tested)
WTwild-type, KPQ Scn5a+/Δ, PES programmed electrical stimulation, BP burst pacing, X failure of a consistent stimulus capture for the duration
of each experiment in the presence of 3 μM flecainide for the KPQ group
Table 3 Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of flecainide (1 and 3 μM)
Procedure N Condition Mean arrhythmic episode duration (s)
Overall 0.2–1.0 1.1–5.0 5.1–10.0 10.0 +
WT
8 Hz PES 11 Control 4.3±1.1 3.8±1.0 0.3±0.2 0.0 0.2±0.1
6 Flecainide 1 μM 1.2±0.5 0.7±0.3* 0.5±0.5 0.0 0.0
5 Flecainide 3 μM 0.0* 0.0* 0.0 0.0 0.0
10 Hz PES 11 Control 8.8±1.0 8.1±1.1 0.5±0.3 0.1±0.1 0.1±0.1
6 Flecainide 1 μM 2.3±1.5** 1.5±1.0** 0.8±0.8 0.0 0.0
5 Flecainide 3 μM 0.0*** 0.0*** 0.0 0.0 0.0
BP 11 Control 3.8±0.8 2.7±1.0 0.3±0.1 0.4±0.2 0.5±0.4
6 Flecainide 1 μM 1.0±0.8 0.0 0.8±0.7 0.2±0.2 0.0
5 Flecainide 3 μM 0.0* 0.0 0.0 0.0 0.0
KPQ
8 Hz PES 6 Control 4.5±1.7 4.0±1.71 0.5±0.3 0.0 0.0
6 Flecainide 1 μM 0.0* 0.0* 0.0 0.0 0.0
6 Flecainide 3 μMX X X X X
10 Hz PES 6 Control 1.8±0.9 1.0±0.4 0.8±0.5 0.0 0.0
6 Flecainide 1 μM 0.0 0.0* 0.0 0.0 0.0
6 Flecainide 3 μMX X X X X
BP 6 Control 0.2±0.2 0.2±0.2 0.0 0.0 0.0
6 Flecainide 1 μM 0.0 0.0 0.0 0.0 0.0
6 Flecainide 3 μMX X X X X
Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia
durations under different conditions obtained during PES conducted at 8, 10 Hz and BP. The results of one-way ANOVA for correlated samples
are shown and compare arrhythmogenic incidences between control and flecainide for WT (top panel) and KPQ (bottom panel) groups
WT wild-type, KPQ Scn5a+/Δ, PES programmed electrical stimulation, BP burst pacing, N Numbers of hearts used for each condition, X loss of
capture with 3 μM flecainide for KPQ preparations
*P<0.05, **P<0.005, ***P<0.0005
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genic than KPQ preparations, whether for PES conducted at
8H z( P=0.007), 10 Hz (P=0.01)andBP(P=0.008). In WT
hearts, quinidine reduced the number of WT hearts showing
at least one arrhythmic episode whatever the procedure, with
3 μMm o r ep o t e n tt h a n1μM, to give a significant difference
between test and control conditions with PES conducted at
10 Hz (P=0.002). KPQ hearts showed low incidences of
arrhythmogenesis both before and after quinidine treatment,
which made distinguishing the incidences of hearts showing
atrial arrhythmias difficult. Nevertheless, quinidine tended to
diminish this incidence, with none of the KPQ hearts
displaying arrhythmias after addition of 3 μM quinidine.
BP proved to be less effective in inducing arrhythmogenesis
in both experimental groups.
Table 4 shows the mean overall incidence of atrial
arrhythmic episodes per heart in WT and KPQ groups in
t h ep r e s e n c ea n da b s e n c eo f1a n d3μM quinidine. In WT
hearts, the presence of 1 μM quinidine significantly
reduced the average total incidence of arrhythmic episodes
per heart only for PES performed at 10 Hz (P=0.01),
while 3 μM quinidine reduced the average total incidence
of arrhythmic episodes per heart for PES conducted at
stimulation frequencies of 8 Hz (P=0.008), 10 Hz (P<
0.0001) and BP (P=0.02). The control mean total
incidence of arrhythmic episodes per heart in KPQ hearts
for a PES protocol was very small when compared to that
in WT preparations, and no atrial arrhythmogenesis was
detected with a BP procedure. Addition of quinidine did
not result in any significant changes in the mean total
Table 4 Overall and average incidences of atrial arrhythmogenic episodes in the presence and absence of quinidine (1 and 3 μM)
Procedure N Condition Mean arrhythmic episode duration (s)
Overall 0.2–1.0 1.1–5.0 5.1–10.0 10.0 +
WT
8 Hz PES 6 Control 6.8±1.9 5.3±1.9 0.8±0.4 0.2±0.2 0.5±0.3
6 Quinidine 1 μM 4.0±0.6 2.7±0.4 0.3±0.3 0.8±0.4 0.2±0.2
6 Quinidine 3 μM 0.3±0.2* 0.3±0.2* 0.0 0.0 0.00
10 Hz PES 6 Control 9.7±0.7 7.3±1.5 1.3±0.8 0.3±0.3 0.7±0.5
6 Quinidine 1 μM 4.5±1.6* 3.7±1.2 0.3±0.3 0.5±0.3 0.00
6 Quinidine 3 μM 0.0*** 0.0** 0.0 0.0 0.00
BP 6 Control 0.8±0.3 0.3±0.2 0.2±0.2 0.2±0.2 0.2±0.2
6 Quinidine 1 μM 0.5±0.2 0.3±0.2 0.0 0.2±0.2 0.0
6 Quinidine 3 μM 0.0* 0.0 0.0 0.0 0.0
KPQ
8 Hz PES 10 Control 0.3±0.2 0.2±0.2 0.1±0.1 0.0 0.0
5 Quinidine 1 μM 1.0 1.0 0.0 0.0 0.0
5 Quinidine 3 μM 0.0 0.0 0.0 0.0 0.0
10 Hz PES 10 Control 0.6±0.4 0.6±0.4 0.0 0.0 0.0
5 Quinidine 1 μM 0.0 0.0 0.0 0.0 0.0
5 Quinidine 3 μM 0.0 0.0 0.0 0.0 0.0
BP 10 Control 0.0 0.0 0.0 0.0 0.0
5 Quinidine 1 μM 0.0 0.0 0.0 0.0 0.0
5 Quinidine 3 μM 0.0 0.0 0.0 0.0 0.0
Mean overall incidence and mean average arrhythmogenic incidences per heart broken down in four different categories of atrial arrhythmia (AA)
durations under different conditions obtained during PES conducted at 8 Hz, 10 Hz and BP. The results of one-way ANOVA for correlated
samples are shown and compare arrhythmogenic incidences between control and quinidine for WT (top panel) and KPQ (bottom panel) groups
WT wild-type, KPQ Scn5a+/Δ, PES programmed electrical stimulation, BP burst pacing, N Numbers of hearts used for each condition
*P<0.05, **P<0.005, ***P<0.0005
Table 5 Numbers of WT and KPQ hearts showing one or more arrhythmogenic episodes in the presence and absence of quinidine (1and 3 μM)
WT KPQ
Control Quinidine 1 μM Quinidine 3 μM Control Quinidine 1 μM Quinidine 3 μM
PES (8 Hz) 6/6 6/6 2/6 2/10 1/5 0/5
PES (10 Hz) 6/6 4/6 0/6 3/10 0/5 0/5
BP 4/6 3/6 0/6 0/10 0/5 0/5
Numbers of hearts in which at least one episode of AT occurred/total number of preparations studied under that condition
450 Pflugers Arch - Eur J Physiol (2009) 458:443–457incidence of arrhythmic episodes per heart for either BP or
PES.
Table 4 also summarises the effect of quinidine on mean
incidence of arrhythmic episodes per heart for each of the
four different categories of arrhythmic durations. Quinidine
(3 μM) significantly reduced the appearance only of
arrhythmic episodes lasting ≤1 s for PES conducted at both
8H z( P=0.03) and 10 Hz (P=0.0007) stimulation frequen-
cies in WT hearts, but not for BP. Quinidine (1 μM) in WT
hearts had no significant effect on the mean incidence of
arrhythmic episodes per heart for any of the four different
categories for either PES or BP. Quinidine (1 and 3 μM) in
KPQ preparations did not have any significant effect on the
mean incidence of arrhythmic episodes per heart for any of
the four different categories for either PES or BP.
Atrial monophasic action potential durations are longer
in KPQ than in WT hearts
Figure 4 illustrates the effects of flecainide and quinidine on
atrial action potential durations at the 90% repolarisation
level (APD90) in WT and KPQ hearts. In these experiments,
hearts were regularly paced at 8 Hz; at the faster pacing
frequency of 10 Hz, it was often not possible clearly to
demonstrate full recovery of the action potential to baseline,
which was necessary for a full characterisation of APD90
values. It displays action potential waveforms in WT (A)
and KPQ hearts (B), before (a) and following addition of
flecainide (b) and quinidine (c). Flecainide 3 μM (Ab and
open bars in C) significantly prolonged APD90 in WT
hearts (P<0.0001) from 22.1±0.4 (n=13, seven hearts) to
27.3±0.8 (n=13, six hearts) but failed to ensure consistent
capture in KPQ hearts. A lower concentration of 1 μM
flecainide did not change APD90 in KPQ hearts, with
values for mean APD90 being 24.5±0.3 (n=17, ten hearts)
before and 23.9±0.7 (n=11, seven hearts) after addition of
the drug (Bb and open bars in C). Monophasic action
potential waveforms (MAPs) recorded during regular
pacing at 8 Hz in WT and KPQ hearts both significantly
(P<0.0001 for both groups) increased in duration on
addition of 3 μM quinidine (c, A and B, respectively, black
bars in C) from 22.1±0.4 (n=13, seven hearts) to 31.0±0.6
(n=8, four hearts) and 24.5±0.3 (n=17, ten hearts) to 32.3±
0.6 (n=7, four hearts), respectively. Figure 4C also shows
that control mean APD90 was significantly (P<0.0001 (#))
longer in KPQ (24.5±0.3 (n=17, ten hearts)) when
compared to WT (22.1±0.4 (n=13, seven hearts)) hearts.
KPQ hearts have longer atrial refractory periods
than WT hearts
In contrast to previous studies of ventricular arrhythmo-
genesis [39, 40], the present experiments demonstrated that
KPQ hearts showed a reduced propensity to atrial arrhyth-
mogenesis compared to WT, and this tendency was reduced
further by both flecainide and quinidine in both genetic
variants. Yet KPQ hearts also showed increased atrial
APD90 values compared to WT hearts. Furthermore,
flecainide and quinidine exerted anti-arrhythmic effects in
both KPQ and WT. Yet flecainide also increased APD90 in
WT, and both flecainide and quinidine increased APD90 in
KPQ hearts. However comparisons of refractory periods in
KPQ and WT hearts provided possible correlates with their
contrasting arrhythmogenic properties. Thus, Fig. 5 shows
significantly longer mean AERPs in KPQ hearts compared
to WT hearts when these were subject to PES conducted at
either 8 or 10 Hz stimulation frequencies (P<0.0001 for
both). AERP observed at 8 Hz in WT hearts was 14.0±1.0
Fig. 4 Effect of flecainide and quinidine on atrial APDs in WT and
KPQ hearts. MAPs recorded during regular pacing at 8 Hz in WT (A)
and KPQ (B) hearts before (a, A and B) and after addition of 1 μM
(B, b) and 3 μM( A, b) flecainide and 3 μM quinidine (c, A and B).
The bar chart (C) summarises effect of 1 μM flecainide (open bars;
KPQ) and 3 μM flecainide (WT) and 3 μM quinidine (black bars)o n
mean APD90 of both experimental groups. Stars represent significant-
ly different results (*P<0.0001) between control (dashed bars) and
drug-treated mean APD90 within each experimental group, while #
indicates significantly different control mean APD90 between WT and
KPQ hearts (#P<0.0001)
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21.3±0.7 ms (n=41, 16 hearts). At 10 Hz, these values were
13.7±0.8 ms (n=33, 15 hearts) and 21.2±0.8 (n=43, 15
hearts) in WT and KPQ experimental groups, respectively.
Flecainide and quinidine both prolong the refractory
periods in both WT and KPQ hearts
Figure 5 also shows effect of 1 and 3 μM flecainide on
AERP in WT and KPQ hearts obtained during PES
conducted at 8 Hz (A) and 10 Hz (B) stimulation
frequencies. A highly significant increase in AERP from
14.0±1.0 ms (n=30, eight hearts) to 29.9±2.5 (n=14, five
hearts) and from 13.7±0.8 ms (n=33, 15 hearts) to 45.3±
4.7 (n=17, six hearts) was observed in WT hearts at 8 and
10 Hz, respectively, on addition of 1 μM flecainide (P<
0.0001 for both frequencies). Flecainide (3 μM) further
significantly increased AERP to 58.4±4.3 (n=9, three
hearts) and 75.0±5.9 (n=8, three hearts) at stimulation
frequencies of 8 and 10 Hz, respectively (P<0.0001). In
addition, the differences in AERP between results from
using 1 and 3 μM concentrations of the drug were also
significant whether at stimulation frequencies of 8 Hz (P<
0.0001) or 10 Hz (P=0.001). However, KPQ hearts showed
a failure of consistent stimulus capture with 3 μM
flecainide. AERP significantly increased in this group from
21.3±0.7 ms (n=41, 16 hearts) to 45.0±2.7 (n=17, six
hearts) at 8 Hz, and from 21.2±0.8 (n=43, 15 hearts) to
55.5±4.8(n=11, five hearts) at a 10 Hz stimulation frequency
(P<0.0001 for both frequencies) with 1 μM flecainide.
Figure 6 illustrates effects of 1 and 3 μM quinidine on
AERP in WT and KPQ hearts obtained during PES
conducted at 8 Hz (A) and 10 Hz (B) stimulation
frequencies. In WT hearts, a significant increase in AERP
from 13.7±0.8 ms (n=33, 15 hearts) to 19.4±1.2 (n=13,
five hearts) on addition of 1 μM quinidine was only
observed at 10 Hz (P<0.001). AERP further increased to
53.7±2.7 (n=17, six hearts) in addition of 3 μM quinidine
at this frequency (P<0.0001). The same concentration of
quinidine also significantly increased AERP from 14.0±
1.0 ms (n=30, eight hearts) to 35.6±3.5 (n=19, six hearts)
at an 8 Hz stimulation frequency in this experimental group
(P<0.0001). In addition, AERPs obtained at 1 and 3 μM
concentrations of the drug were significantly different
whether at 8 Hz (P= 0 . 0 3 )a n d1 0H z( P<0.0001)
stimulation frequencies. In KPQ hearts a highly significant
increase in AERP from 21.3±0.7 ms (n=41, 16 hearts) to
37.2±4.0 (n=14, four hearts) and from 21.2±0.8 ms (n=43,
15 hearts) to 51.3±8.6 (n=12, four hearts) was observed at
8 and 10 Hz, respectively, in addition of quinidine 1 μM( P<
0.0001 for both frequencies). Quinidine (3 μM) also
significantly increased AERP to 35.4±1.8 (n=15, five
hearts) and 47.7±3.7 (n=15, five hearts) at 8 and 10 Hz,
respectively when compared to control (P<0.0001) in
mutant hearts, doing so to similar extents as obtained with
1 μM quinidine for either frequency (P>0.05).
Arrhythmogenic tendency correlates with increased local
critical intervals
Previous work on murine ventricular arrhythmogenecity [27]
demonstrated increased risks of re-excitation when the APD90
exceeded the ventricular effective refractory period (VERP).
We tested such a hypothesis for the atria studied here by
comparing the above values of atrial APD90 and AERP in
both WT and KPQ groups in the presence and the absence of
flecainide and quinidine. We hypothesised that the risk of
local re-excitation might be reflected in a critical interval (CI)
given by the relevant difference (APD90–AERP).
Figure 7 illustrates typical action potential waveforms
during regular pacing at 8 Hz recorded from WT (A) and
KPQ (B) hearts with the corresponding APD90s (horizontal
broken lines and clear shading), AERPs (horizontal solid
Fig. 5 Effect of flecainide on mean atrial effective refractory periods
(AERP) in WT and KPQ hearts. AERPs observed during 8 Hz (A)a n d
10 Hz (B) PES before (dashed bars) and after addition of 1 μM
flecainide (open bars)a n d3μM flecainide (black bars)t oW Ta n d
KPQ hearts. The results of one-way ANOVA for correlated samples are
shown (***P<0.0001) and compare AERP between control and 1 μM
flecainide and control and 3 μM flecainide for KPQ and WT groups,
respectively. X marking represents loss of capture with 3 μM flecainide
for KPQ preparations. The results comparing control AERP between
WT and KPQ groups are also shown (P<0.0001 (#))
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hashing) shown below each one. Under control conditions,
APD90 in WT (22.1±0.4 ms) and KPQ (24.5±0.3 ms) were
significantly larger than the corresponding AERP (14±1.0
and 21.3±0.7 ms) (A and B, a). However, this difference
was more significant in the WT group than in the KPQ
group (P<0.0001 and P=0.005, respectively). This is
reflected in WT hearts having significantly larger positive
CI values when compared to KPQ hearts (8.1 and 3.2 ms,
respectively; P<0.001) which is clearly demonstrated in a
larger shaded area on the WT group AP waveform (A and
B, a). Flecainide significantly prolonged APD90 in WT but
not in KPQ hearts and significantly increased AERP in both
experimental groups (see findings above). The resulting
negative CIs were −31.1 and −21.1 ms in WT and KPQ
preparations, respectively (P<0.0001 for both), indicating
that the drug prolonged AERP to a much larger extent than
APD90 in both groups. Accordingly, the solid vertical line
(AERP) moved further to the right on action potential
waveform while the position of the dashed vertical line
(APD90) moved slightly to the right (WT) or remained
virtually unchanged (KPQ). Quinidine significantly pro-
longed APD90 in both genetic variants (P<0.0001 for both)
moving the dashed line to the right. However, the drug also
significantly prolonged AERP in the two experimental
groups (P<0.0001 for both), also moving the solid vertical
line to the right. The resulting negative CIs were −4.6 (WT)
and −3.1 ms (KPQ), and were significantly different from
the control data (P<0.001 for both groups). In contrast to
flecainide, quinidine prolonged both APD90 and AERP
similarly in the two groups, which resulted in smaller CI
values that were still negative because the AERPs were
longer than APD90.
Fig. 6 Effect of quinidine on mean AERP in WT and KPQ hearts.
AERPs observed during 8 Hz (A) and 10 Hz (B) PES before (dashed
bars) and after addition of 1 μM quinidine (open bars) and 3 μM
quinidine (black bars) to WT and KPQ hearts. The results of one-way
ANOVA for correlated samples are shown (***P<0.0001, **P<
0.001) and compare AERP between control and 1 μM quinidine and
control and 3 μM quinidine for KPQ and WT groups, respectively.
The results comparing control AERP between WT and KPQ groups
are also shown (#P<0.0001)
Fig. 7 Effect of flecainide and quinidine on mean critical interval in
WT and KPQ hearts. Changes in atrial action potential duration at
90% repolarization (APD90), atrial effective refractory period (AERP),
and local critical interval (CI)i nW T( A) and KPQ (B) hearts before
(a, A and B) and after exposure to flecainide (b, A and B) and
quinidine (c, A and B). MAP waveforms during regular stimulation at
8 Hz frequency in hearts before (a, A and B) and after exposure to
flecainide (b, A and B) and quinidine (c, A and B) comparing APD90
(vertical dashed lines), AERP (vertical solid lines), and local CI
(shading). Asterisks indicate CI values that are significantly (**P<
0.001; ***P<0.0001) different before and after addition of a drug, and
# those that are significantly (#P<0.001) different between WT and
KPQ hearts at baseline
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Human LQT3 syndrome results from ‘gain-of-function’
mutations in the SCN5A gene encoding the pore-forming
α-subunit of the cardiac voltage-gated Na
+ channel,
producing incomplete Na
+ channel inactivation [47]. This
prolongs the cardiac APD in turn predisposing the
myocardium to early EADs that can trigger life-threatening
polymorphic ventricular tachyarrhythmias known as torsade
de pointes [41, 44]. Patients with different LQTS variants
demonstrated abnormalities in atrial physiology similar to
those found in the ventricle in the form of prolonged APD
and RP durations, and EADs triggering ‘atrial torsade de
pointes’ [14]. However, atrial arrhythmias are uncommon
in LQT3 patients [43].
The present experiments accordingly compared atrial
arrhythmogenicity and its physiological basis in isolated
perfused WT and Scn5a+/Δ (KPQ) murine hearts model-
ling human LQT3 for the first time. Experimental con-
ditions thus differed from those used in some recent reports
on atrial arrhythmogenesis of electrocardiographic studies
in intact anaesthetised animals [29, 32, 37] as opposed to
isolated perfused hearts. This may account for some of the
differences in arrhythmogenecity seen in the control
situations between the present and those previous studies.
KPQ mice have previously been shown to provide useful
cardiac models for the investigation of ventricular arrhyth-
mogenesis in LQT3. Their hearts showed a marked
susceptibility to such arrhythmias, in agreement with
clinical findings [12]. Furthermore, pharmacological inter-
vention using the cardiotropic agents flecainide and
quinidine, respectively, alleviated and exacerbated such
arrhythmogenicity [39, 40] likely through actions on
inhomogeneities of APD through the thickness of the
ventricular wall.
However, unlike the ventricle, the murine atrium is a
thin-walled structure unlikely to generate such spatial
heterogeneities between epicardial and endocardial layers.
This difference would be consistent with distinct mecha-
nisms for atrial and ventricular arrhythmogenesis. We
initially assessed atrial arrhythmic tendency in WT and
genetically modified KPQ Langendorff-perfused heart
preparations in the presence and absence of the same
pharmacological interventions as cited above using both
PES and BP protocols. These techniques both showed that
a significantly greater proportion of WT hearts were
arrhythmogenic compared to KPQ hearts. In addition,
where it occurred, the average duration of atrial arrhythmia
was longer in WT when compared to KPQ hearts.
Therefore, it appears that the KPQ mutation exerts a
surprising ‘protective’ effect against atrial arrhythmogene-
sis. This is in sharp contrast to the findings concerning
ventricular arrhythmogenecity.
Furthermore, we demonstrated that the pharmacological
agents described above exerted differing actions on
arrhythmogenecity in the atria when these were compared
to their known ventricular effects whether in WT and KPQ
mouse hearts. Thus, both flecainide and quinidine reduced
or completely eliminated atrial arrhythmogenesis in KPQ
and WT groups. This was in contrast to the action of
flecainide in reducing and that of quinidine in increasing
ventricular arrhythmogencity in KPQ hearts while having
the opposite effects in WT preparations [39, 40].
To account for the differences observed in atria and
ventricles of the same mouse model of LQT3, we went on
to compare particular electrophysiological properties of the
WT and KPQ hearts. Firstly, previous reports have
implicated the ERP in atrial as opposed to ventricular
arrhythmogenicity. Thus, decreases in atrial tissue refracto-
riness and APD are associated with atrial arrhythmogenesis
[1, 6, 7, 22, 24, 33, 45, 48]. The present experiments
similarly associated atrial arrhythmogenicity with short
ERPs. Thus, arrhythmogenic WT hearts had significantly
shorter ERPs when compared to the significantly less
arrhythmogenic KPQ hearts. This is in contrast to findings
in the ventricles in which non-arrhythmogenic WT hearts
had shorter ventricular ERPs when compared to arrhythmo-
genic KPQ preparations [40]. Furthermore, we observed
that flecainide and quinidine significantly increased the
ERP in both WT and KPQ groups in parallel with their
reducing or completely eliminating atrial arrhythmic epi-
sodes in both genetic variants. Again, this contrasts with the
findings in the ventricles, in which the repolarisation
gradient across the ventricular wall was a more consistent
predictor of ventricular arrhythmogeneity than differences
in ERP.
However, despite a number of studies showing that
ventricular arrhythmogenicity in LQTS is associated with
changes in electrical gradient across the ventricular wall
[20, 35, 36], a recent study by Sabir et al. established
another predictor of such arrhythmias in hypokaleimic
mouse hearts [27]. It demonstrated increased tendencies to
local re-excitation and arrhythmogenicity when recovery of
the action potential, measured by its duration at 90%
recovery (APD90), exceeded the corresponding recovery of
excitability, as measured by the VERP. The difference
between the two (APD90−VERP) was represented as a CI.
Positive shifts in CI reflected a relatively proarrhythmic
state, whereas negative shifts reflected an antiarrhythmic
state. We tested this hypothesis in murine atria. According-
ly, we measured atrial effective refractory periods (AERPs)
and APD90s both before and during pharmacological
intervention to obtain atrial CIs for each test condition in
both experimental groups. Our study demonstrated that in
the absence of pharmacological agents the atria of arrhyth-
mogenic WT hearts had larger APD90 values when
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Furthermore,suchbaselinerecordingsshowedthatWThearts
had a significantly larger positive CI value (P<0.001)
when compared to KPQ hearts. This correlated with greater
atrial arrhythmic tendency of the WT preparations.
Furthermore, both flecainide and quinidine were anti-
arrhythmic in either experimental group and produced
significant negative shifts in CI, especially with flecainide.
These findings fulfil expectations from similar reports of
altered ventricular as opposed to atrial arrhythmogenecity
under particular circumstances. Under normal conditions,
local VERP closely corresponds to APD. Thus, previous
studies in ventricles from a range of species reported that
manoeuvres that alter APD also result in corresponding
changes in VERPs [10, 17, 18]. During PES, a premature
extrastimulus shortens RP to a larger extent than APD,
which in turn can induce ventricular arrhythmias [18].
Conversely, Class I cardiotropic drugs could either suppress
or initiate ventricular arrhythmogenesis by altering the
ERP/APD ratio through selective changes in one or other
parameter thereby modifiying post-repolarisation refracto-
riness (PRR) [13, 16]. They then would also be expected to
exert corresponding effects on atrial arrhythmogenecity.
The present studies demonstrated that flecainide exerted
anti-arrhythmic effects. That could also be correlated with the
present findings concerning changes in CI. Thus, flecainide
only significantly increased APD90 in WT but increased
AERP in both WT and KPQ. The result was a negative CI,
These results are in agreement with previous findings on the
effect of flecainide in human atria. For example, Kirchholf et
al (2005) [15] demonstrated that flecainide induced post
recovery refractoriness by prolonging AERP more than
APD90 in fibrillating human atrium and prevented arrhyth-
mia reoccurrence after electrical cardioversion.
Quinidine also decreased arrhythmogenic tendency in
both WT and KPQ hearts, although to a smaller extent than
did flecainide. Quinidine increased both APD90 and AERP,
but exerted a greater effect on AERP, thereby resulting in a
negative CI value, again to a lesser extent than shown in the
presence of flecainide. These findings parallel the effects of
quinidine on ventricular arrhythmogenesis. Thus, quinidine
can promote development of human ventricular arrhythmia
especially during bradycardia by prolonging repolarisation
(APD) and not refractoriness [23, 26]. On the other hand,
once arrhythmia has been initiated after quinidine admin-
istration, it can often be suppressed by pacing the heart at
high rates [26]. This can be attributed to it having a more
marked effect on VERP than on APD with increasing heart
rate resulting in a protective effect [23, 11].
In summary, this study compared for the first time the
effects of flecainide and quinidine on the electrophysiolog-
ical properties of WT and genetically modified (Scn5a+/Δ)
mice lacking the same KPQ residues as LQT3 patients [25].
It appears that KPQ mutation, while predisposing to
ventricular arrhythmias, has a ‘protective’ effect for atrial
arrhythmogenicity. Therefore, our investigation shows that
factors previously known to determine arrhythmias in
ventricles do not necessarily determine atrial arrhythmo-
genic tendency. Nevertheless, the present findings bearing
on atrial arrhythmogenecity could be correlated with
corresponding criteria developed for ventricular arrhythmo-
genesis in one important respect: prolonging RP beyond
APD may be beneficial for prevention of atrial arrhythmias.
Therefore, agents that promote post recovery refractoriness
and shift CI in the negative direction may be a good target
for development of drugs aimed at preventing atrial
arrhythmogenesis.
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